Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
𝛼
SK
or Search
SIGN UP
SIGN IN
ENTITY
Symbio Pharmaceuticals (4582 JP)
Watchlist
43
Analysis
Health Care
•
Japan
Symbio Pharmaceuticals Limited develops and commercializes prescription drugs n oncology, hematology and auto-immune disease for Japan and other Asia Pacific markets.
more
Watchlist
All
Insights
Primers
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Symbio Pharmaceuticals
•
14 Dec 2017 16:58
•
Issuer-paid
SymBio Pharmaceuticals - Licence agreement for IONSYS terminated
The licence agreement between SymBio and The Medicines Company (MDCO) for the exclusive rights to develop the IONSYS (SyB P-1501) pain patch in...
Edison Investment Research
Follow
133 Views
Share
bullish
•
Symbio Pharmaceuticals
•
02 Nov 2017 18:45
•
Issuer-paid
SymBio Pharmaceuticals - New formulations extend Treakisym patent life
SymBio has substantially increased the value of its Treakisym franchise through in-licensing novel bendamustine formulations from Eagle...
Edison Investment Research
Follow
126 Views
Share
bullish
•
Symbio Pharmaceuticals
•
24 Oct 2017 06:20
•
Issuer-paid
New formulations extend Treakisym patent life
SymBio has substantially increased the value of its Treakisym franchise through in-licencing novel bendamustine formulations from Eagle...
Edison Investment Research
Follow
193 Views
Share
bullish
•
Symbio Pharmaceuticals
•
27 Feb 2017 22:00
•
Issuer-paid
Moving ahead on all fronts
During 2017 we expect updates on all three of SymBio’s main assets. We expect Treakisym sales growth via partner Eisai following approvals during...
Edison Investment Research
Follow
219 Views
Share
bullish
•
Symbio Pharmaceuticals
•
27 Feb 2017 17:01
•
Issuer-paid
Moving ahead on all fronts
During 2017 we expect updates on all three of SymBio’s main assets. We expect Treakisym sales growth via partner Eisai following approvals during...
Edison Investment Research
Follow
116 Views
Share
First
Previous
3
4
5
6
7
8
9
Next
Last
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
How Smartkarma Compares
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.5
x